Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.

At 2 days post-challenge, intramuscularly vaccinated mice showed a trend of higher acute inflammation scores than the intranasal group (although this difference was not determined to be statistically significant), suggesting that our intranasal vaccine might better protect mice from early development of lung infection than IM mRNA, perhaps due to the route of administration and localized immune responses ( Fig.7 B).

also in 53,322 other papers